Emily Chan

4.5k total citations · 2 hit papers
46 papers, 2.9k citations indexed

About

Emily Chan is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Emily Chan has authored 46 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 15 papers in Molecular Biology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Emily Chan's work include Colorectal Cancer Treatments and Studies (19 papers), Colorectal and Anal Carcinomas (8 papers) and Cancer Treatment and Pharmacology (8 papers). Emily Chan is often cited by papers focused on Colorectal Cancer Treatments and Studies (19 papers), Colorectal and Anal Carcinomas (8 papers) and Cancer Treatment and Pharmacology (8 papers). Emily Chan collaborates with scholars based in United States, United Kingdom and Spain. Emily Chan's co-authors include Mark Merchant, Jeff Settleman, Marc Peeters, Andrés Cervantes, Timothy Price, Florian Lordick, Yevhen Hotko, Thierry André, Laslo Roman and Michel Ducreux and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Blood.

In The Last Decade

Emily Chan

46 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

2012 884 citations Timothy R. Wilson, Jane Fridlyand et al. Nature profile →
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

2010 755 citations Marc Peeters, Timothy Price et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Emily Chan

Since Specialization

Citations

This map shows the geographic impact of Emily Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Chan more than expected).

Fields of papers citing papers by Emily Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Chan. The network helps show where Emily Chan may publish in the future.

Co-authorship network of co-authors of Emily Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Emily Chan. A scholar is included among the top collaborators of Emily Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily Chan. Emily Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer 2025 ·Journal of Clinical Oncology ·Filippo Pietrantonio, Lisa Salvatore, Taito Esaki, Dominik Paul Modest, D. Páez López-Bravo, Julien Taı̈eb, Michalis V. Karamouzis, Erika Ruíz‐García, Tae Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun‐Huei Yeh, Emily Chan, Joseph Chao, Qui Tran, Chiara Cremolini, Marwan Fakih	7
2	Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial 2025 ·The Lancet Oncology ·Dominik Paul Modest, Marwan Fakih, Lisa Salvatore, Taito Esaki, D. Páez López-Bravo, Julien Taı̈eb, Michalis V. Karamouzis, Erika Ruíz‐García, (unknown), Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun‐Huei Yeh, Chiara Cremolini, Qui Tran, Emily Chan, Joseph Chao, István Májer, Filippo Pietrantonio	1
3	91MO Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study 2023 ·Annals of Oncology ·Yasutoshi Kuboki, Filippo Pietrantonio, Lisa Salvatore, Taito Esaki, Dominik Paul Modest, David Páez, Julien Taı̈eb, (unknown), Tae Won Kim, Fausto Meriggi, David Cunningham, Kun‐Huei Yeh, Emily Chan, Joseph Chao, (unknown), (unknown), (unknown), Chiara Cremolini, Marwan Fakih	1
4	KontRASt-02: A Phase III Trial Investigating the Efficacy and Safety of the KRASG12C Inhibitor JDQ443 vs. Docetaxel in Patients with Previously Treated, Locally Advanced or Metastatic, KRAS G12C-Mutated NSCLC 2023 ·International Journal of Radiation OncologyBiologyPhysics ·Federico Cappuzzo, Gilberto de Castro, Jin‐Hyoung Kang, Yi‐Long Wu, Odd Terje Brustugun, Parneet Cheema, Taofeek K. Owonikoko, (unknown), (unknown), Rafael Caparica, Herbert H. Loong, Emily Chan	2
5	Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation 2019 ·Cell Reports ·Denise E. de Almeida Nagata, Eugene Y. Chiang, Suchit Jhunjhunwala, Patrick Caplazi, (unknown), Zora Modrušan, Emily Chan, Mark Merchant, Lingyan Jin, David Arnott, F. Anthony Romero, Steven Magnuson, Karen E. Gascoigne, Jane L. Grogan	54
6	Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors 2017 ·Cancer Chemotherapy and Pharmacology ·Emily Chan, E. Gabriela Chiorean, Peter J. O’Dwyer, Nashat Gabrail, Thierry Alcindor, Diane Potvin, Richard C. Chao, Herbert I. Hurwitz	36
7	Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer 2016 ·Radiotherapy and Oncology ·Emily Chan, Lori R. Arlinghaus, Dana B. Cardin, Laura W. Goff, Jordan Berlin, Alexander A. Parikh, Richard G. Abramson, Thomas E. Yankeelov, Scott W. Hiebert, Nipun B. Merchant, Srividya Bhaskara, Anuradha Chakravarthy	59
8	Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial 2015 ·The Lancet Oncology ·Julio García‐Aguilar, Lindsay A. Renfro, Oliver S. Chow, Qian Shi, Xiomara W. Carrero, Patricio B. Lynn, Charles R. Thomas, Emily Chan, Peter A. Cataldo, Jorge Marcet, David Medich, Craig S. Johnson, Samuel Oommen, Bruce G. Wolff, Alessio Pigazzi, Shane McNevin, (unknown), Ronald Bleday	256
9	Relationship between metformin use and recurrence and survival in patients (pts) with resected stage III colon cancer (CC) receiving adjuvant chemotherapy: Results from NCCTG N0147 (Alliance). 2015 ·Journal of Clinical Oncology ·Preet Paul Singh, Qian Shi, Nathan R. Foster, Axel Grothey, Suresh Nair, Emily Chan, Anthony F. Shields, Richard M. Goldberg, Sharlene Gill, Morton S. Kahlenberg, Frank A. Sinicrope, Daniel J. Sargent, Steven R. Alberts	4
10	Immunotherapy with Long-Lived Anti-CD123 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123+ Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia 2014 ·Blood ·Seung Y. Chu, Erik Pong, Hsing Chen, Sheryl Phung, Emily Chan, (unknown), Rumana Rashid, Christine Bonzon, Irene Leung, Umesh S. Muchhal, Gregory L. Moore, Matthew J. Bernett, David E. Szymkowski, John R. Desjarlais	34
11	Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer 2013 ·Annals of Oncology ·Brian M. Wolpin, Eileen M. O’Reilly, Yoo-Joung Ko, Lawrence S. Blaszkowsky, Mark U. Rarick, Caio Rocha‐Lima, Paul S. Ritch, Emily Chan, Jennifer L. Spratlin, Teresa Macarulla, Elaine McWhirter, Denis Pezet, Mikhail Lichinitser, Laslo Roman, Alan C. Hartford, Kendall Morrison, (unknown), M. Vincent, Leonard Reyno, Manuel Hidalgo	29
12	Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer 2013 ·Annals of Oncology ·Marc Peeters, Timothy Price, Andrés Cervantes, Alberto Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, A. H. Strickland, G. Wilson, Tudor–Eliade Ciuleanu, Laslo Roman, Eric Van Cutsem, Yong‐Sheng Tian, R. Sidhu	158
13	A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study. 2013 ·Journal of Clinical Oncology ·Deirdre Jill Cohen, Paul J. Christos, Joseph A. Sparano, Hedy L. Kindler, Daniel Virgil Thomas Catenacci, Tanios Bekaii‐Saab, Sanaa Tahiri, Yelena Y. Janjigian, Michael K. Gibson, Emily Chan, Lakshmi Rajdev, Susan G. Urba, James L. Wade, Peter Kozuch, (unknown), Katherine Vandris, Naoko Takebe, Howard S. Höchster	16
14	Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer 2013 ·European Journal of Cancer ·Jeffrey R. Infante, Johanna C. Bendell, Laura W. Goff, Suzanne F. Jones, Emily Chan, (unknown), Howard A. Burris, Jordan Berlin	10
15	Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M 2012 ·Cancer Discovery ·Ho‐June Lee, Gabriele Schaefer, Timothy P. Heffron, Lily Shao, Xiaofen Ye, Steve Sideris, Shiva Malek, Emily Chan, Mark Merchant, Hank La, Savita Ubhayakar, Robert L. Yauch, Valentina Pirazzoli, Katerina Politi, Jeff Settleman	68
16	Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors breakdown → 2012 ·Nature ·Timothy R. Wilson, Jane Fridlyand, Yibing Yan, Elicia Penuel, Luciana Burton, Emily Chan, Jing Peng, Eva Lin, Yulei Wang, Jeff Sosman, Antoni Ribas, Li Jiang, John G. Moffat, Daniel P. Sutherlin, Hartmut Koeppen, Mark Merchant, Richard M. Neve, Jeff Settleman	884
17	A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors 2012 ·Cancer Chemotherapy and Pharmacology ·Stephen Leong, Sabine Eckhardt, Emily Chan, Wells A. Messersmith, Jennifer L. Spratlin, D. Ross Camidge, Sami Diab, Reza Khosravan, Xun Lin, Edna Chow Maneval, A. Craig Lockhart	7
18	Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer breakdown → 2010 ·Journal of Clinical Oncology ·Marc Peeters, Timothy Price, Andrés Cervantes, Alberto Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, Andrew Strickland, G. Wilson, Tudor–Eliade Ciuleanu, Laslo Roman, Eric Van Cutsem, Valentina Tzekova, Simon Collins, Kelly S. Oliner, Alan Rong, Jennifer Gansert	755
19	Advances in oncology. Panitumumab and combination chemotherapy in first- and second-line therapy for colorectal cancer. 2010 ·PubMed ·Emily Chan	2
20	A Phase I Trial of Irinotecan Alternating With Epirubicin in Patients With Advanced Malignancies 2008 ·American Journal of Clinical Oncology ·Laura W. Goff, Mace L. Rothenberg, A. Craig Lockhart, Bruce J. Roth, (unknown), Emily Chan, Jordan Berlin	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact